Loading stock data…
IRON
$68.34+2.54 (+3.86%)
After Hours$68.34+0.00 (+0.00%)· Last close Jun 9
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Disc Medicine, Inc. in the Healthcare sector is trading at $68.34 with a market capitalization of $2.7B. Wall Street consensus targets $101.09 (11 analysts), implying a +47.9% move over the next 12 months. The stock is currently 31% below its 52-week high of $99.50, remaining 6.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +47.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$68.34
Potential Downside
0%
Whystock Fair Value$68.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$101.09+47.9%
Range$79.00 – $128.00
Fundamentals
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United S...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.66B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.14
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.09%
Volume
Today's trading volume
582,239
Recent News
How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients
Disc Medicine has launched a U.S. expanded access program for its investigational drug bitopertin, allowing eligible erythropoietic protoporphyria and X-linked protoporphyria patients aged 12 and above to receive treatment outside ongoing Phase 3 trials. This move highlights how rare-disease drug developers may use expanded access programs to address urgent patient needs while pivotal APOLLO trial data and an eventual FDA decision are still pending. We’ll now examine how offering...
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges
Disc Medicine (NASDAQ:IRON) Chief Executive Officer John Quisel said patient demand for the company’s bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company enrolled 183 patients in the APOLLO confirmatory study, above its original target of 150. Speaking at a
A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter
Disc Medicine (IRON) stock has been in focus after law firms began investigating potential securities claims linked to allegedly misleading business information following an FDA Complete Response Letter on its bitopertin program. See our latest analysis for Disc Medicine. At a share price of $67.59, Disc Medicine has had a 3.70% 1 month share price return but a 17.22% 3 month share price decline. The 1 year total shareholder return of 58.76% and 3 year total shareholder return of about 2x...
Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge
Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains.
Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals
Event Overview and Immediate Context Disc Medicine (IRON) has drawn fresh attention after recent share price moves, with the stock up about 3% over the past day but showing a negative return over the past month and past 3 months. See our latest analysis for Disc Medicine. The latest 3.0% 1 day share price return and 2.8% 7 day share price return sit against weaker recent momentum, with the 30 day and 90 day share price returns both negative while the 1 year and 3 year total shareholder...